about
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment...
Read More
160.39
4.07
(2.60%)
2.7M
XNAS Volume
XNAS 22 Jan, 2026 4:11 PM (EST)
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution
View Similar
Embed DVM
Insmed Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..